The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia

Human Vaccines

Volumn 4, Issue 3, 2008, Pages 238-245

  Brisson, Marc ^a,b   Pellissier, James M ^c   Camden, Stéphanie ^b   Quach, Caroline ^d   De Wals, Philippe ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Cost effectiveness; Economic evaluation; Herpes zoster; Mathematical model; Post herpetic neuralgia (PHN); Vaccines; Varicella zoster virus (VZV)

Indexed keywords

HERPES VACCINE; VARICELLA ZOSTER VACCINE;

AGE; ARTICLE; CANADA; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HERPES SIMPLEX; HUMAN; POSTHERPETIC NEURALGIA; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; VACCINATION; ADULT; AGED; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HERPES ZOSTER; IMMUNOLOGY; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; VARICELLA ZOSTER VIRUS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CANADA; COST-BENEFIT ANALYSIS; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; QUALITY-ADJUSTED LIFE YEARS; VACCINATION;

EID: 48249131166     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.3.5686     Document Type: Article

References (43)

1. Gnann JW Jr, Whitley R. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340-6.
2. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127:305-14.
3. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25:571-5.
4. de Moragas JM, Kierland RR. The outcome of patients with herpes zoster. AMA Arch Dermat 1957; 7:193-6.
5. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes Zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19:3076-90.
6. Yawn B, Wollan P, Saint Sauver J, Kurland M, Sy LS and Saddier P. Herpes zoster in the community. North American Primary Care Research Group meeting; 2006; Tucson, AZ, USA.
7. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
8. Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005; 23:2470-6.
9. National Advisory Committee on Immunization (NACI). Statement on Human Papillomavirus Vaccine. Canada Communicable Disease Report 2007; 33.
10. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145:317-25.
11. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44:1280-8.
12. Pellissier JM, Brisson M, Levin MJ. Evaluation of the Cost-Effectiveness in the U.S. of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine 2007; 25:8326-37.
13. Bala M, Wood L, Zarkin GA, Norton EC, Gafni A, O'Brien BJ. Valuing outcomes in health care: A comparison of willingness-to-pay and quality-adjusted life years. J Clin Epidemiol 1998; 51:667-76.
14. Oster G, Harding G, Dukes E, Edelsberg J., Geary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey. Journal of Pain 2005; 6:356-63.
15. Coplan PM, Schmader K, Nikas A, Chan ISF, Choo PW, Levin MJ et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the Brief Pain Inventory. J Pain 2004; 5:344-56.
16. Brisson M, Pellissier JM, Levin MJ. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis 2007; 45:1527-9.
17. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20:1113-25.
18. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. Available: www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf (accessed 2007 October 5).
19. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunisation on the epidemiology of varicella zoster virus. Epidemiol Infect 2000; 125:651-69.
20. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20:748-53.
21. Russell ML, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect 2007; 135:908-13.
22. de Melker H, Berbers G, Hahne S, Rumke H, van den Hof S, de Wit A, Boot H. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006; 24:3946-52.
23. Brisson M, Edmunds WJ. Epidemiology of Varicella-Zoster Virus in England and Wales. J Med Virol 2003; 70:9-14.
24. Insinga RP, Itzler RF, Pellissier JM. Acute/Subacute Herpes Zoster: Healthcare Resource Utilisation and Costs in a Group of US Health Plans. Pharmacoeconomics 2007; 25:155-69.
25. Canadian Institute for Health Information (CIHI). Hospital Morbidity Database (HMDB), 2000-2003. Available: http://secure.cihi.ca/cihiweb/dispPage. jsp?cw_page=statistics_results_source_hmdb_e&cw_topic= Hospital%20Morbidity%20database%20(HMDB) (accessed 2007 October 5).
26. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the evaluation of health care programmes. New York: Oxford University Press; 1997.
27. Brisson M, Johnson RW, Levin MJ, Oxman MN, Schmader KE, Patrick DM, Koch C, Senecal M, Mansi JA. Measuring Herpes Zoster (HZ) and Post-Herpetic Neuralgia (PHN) Associated Burden of Illness, Health Care Utilization and Costs in Canada: A Clinical Epidemiological Study. Can J Infect Dis Med Microbiol 2006; 17:381.
28. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000; 321:794-6.
29. Statistics Canada. Consumer Price Index. Available: www.statcan.ca/ english/Subjects/Cpi/cpi-en.htm (accessed 2007 October 5).
30. Nowgesic E, Skowronski D, King A, Hockin J. Direct costs attributed to chickenpox and herpes zoster in Bristish Columbia: 1992-1996. Can Commun Dis Rep 1999; 25:100-4.
31. Canadian Institute for Health Information (CIHI). Reciprocal Billing Report, Canada, 2003-2004. Available: http://dsp-psd.pwgsc.gc.ca/Collection/ H115-9-2004E.pdf (accessed 2007 October 5).
32. White RR, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW. Annual healthcare cost of herpes zoster (shingles) and its complications. International Society for Infectious Diseases 12th International Congress on Infectious Disease 2006; Lisbon, Portugal.
33. Centers for Disease Control and Prevention (CDC). Vaccines and Immunizations: CDC Vaccine Price List. Available: www.cdc.gov/vaccines/programs/ vfc/cdc-vac-price-list.htm (accessed 2007 October 5).
34. WHO (World Health Organization). Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva, Switzerland 2001.
35. WHO (World Health Organization). WHO-CHOICE: World Health Organization statistical information system: Choosing interventions that are Cost Effective. Available: http://www.who.int/choice/en (accessed 2007 October 5).
36. Baldwin JR, Brown M, Maynard JP. Insights on the Canadian Economy: Interprovincial Differences in GDP per Capita, Labour Productivity and Work Intensity: 1990-2003. StatCan Catalogue no. 11-624-MIE-No.011, 2005.
37. De'ath D, Fabricius KE. Classification and Regression Trees: A Powerful Yet Simple Technique for Ecological Data Analysis. Ecology 2000; 81:3178-92.
38. Statistics Canada. Complete life table, Canada, 2000 to 2002. Available: http://www.statcan.ca/ (accessed 2007 October 5).
39. Brisson M, Edmunds WJ. Varicella Vaccination in England and Wales: Cost-utility analysis. Arch Dis Child 2003; 88:862-9.
40. Dworkin RH, Boon RJ, Griffin DRG, Phung D. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998; 178:276-80.
41. Mauskopf J, Austin R, Dix L, Berzon R. The Nottingham health profile as a measure of quality of life in zoster patients: convergent and discriminant validity. Qual Life Res 1994; 3:431-5.
42. Paparatti UL, Arpinelli F, Visona G. Herpes zoster and its complications in Italy: an observational survey. J Infect 1999; 38:116-20.
43. Aoki FY, Peterson S, Black C. Pharmacoepidemiology of Herpes zoster treatment with antiviral drugs in Manitoba: a population-based study, 1996-2001. 25th Anniversary Meeting of the Canadian Society for Clinical Pharmacology 2003; Ottawa, Canada.